
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has seen a significant appreciation in its stock value, with shares rising nearly 90% in the past month, indicating strong investor confidence. The company's multi-cancer early detection technologies position it strategically within a lucrative market, projected to reach approximately $3.7 billion in the UK by 2026 and grow further to $4.0 billion by 2035. Furthermore, partnerships to capitalize on this total addressable market (TAM) and the recent positive data readout from the PATHFINDER 2 study bolster the outlook for GRAIL, even amid uncertainties regarding regulatory approvals and Medicare reimbursement.
Bears say
GRAIL Inc has consistently reported substantial net losses since its inception and is likely to continue incurring such losses due to ongoing studies and regulatory processes necessary for its multi-cancer early detection blood test. The company faces multiple significant risks, including potential delays in receiving Medicare reimbursement for its tests, adoption challenges for its innovative product, and competition from larger, established players in the diagnostics market, which could hinder its commercialization efforts. Additionally, challenges related to high selling, general, and administrative expenses and possible delays in clinical studies further exacerbate the company’s financial outlook, raising concerns about its ability to secure necessary financing for future growth.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares